|
Search for Cases |
|
Case Details |
|
Case Code: LDEN136
|
Case Length: 17 Pages |
Period: 2018 |
Pub Date: 2019 |
Teaching Note: Available |
Price: Rs.500 |
Organization : Dr. Reddy’s Laboratories Ltd
|
Industry :Pharmaceuticals |
Countries : India; United States; Germany |
Themes:
|
|
|
|
Dr. Reddy`s Laboratories: Challenges ahead for Erez Israeli |
|
|
|
<<Previous Page |
EXCERPTS |
|
|
In March 2018, Mukherjee retired as the Chief Operating Officer, a position he had held since 2014. He played an instrumental role in the growth of the company, especially during the acquisition of Roche’s API Business in Mexico and the acquisition of Dow pharma’s UK-based small molecule business. He also led the strategic alliance with GSK for Emerging Markets. He served as the President of PSAI and as the President of Developing Businesses of DRL. Mukherjee earned the reputation of being a seasoned marketer with superior technical knowledge, having completed his graduation in Chemical Engineering from the Indian Institute of Technology, Kharagpur...
|
|
|
or |
|
or |
PayPal (11 USD)
|
|
|
|
|
Analysts believed that there might not be a simple solution to the price control and with the US Generic industry showing clear signs of hitting a plateau in terms of sales, Israeli would be tested on the quality of the products. He along with the management council needed to build a culture of compliance, especially on the manufacturing and quality sides, in order to steer clear of the surprise audits. Industry analysts felt Israeli along with the management council needed to create a culture of transparency and compliance... |
|
|
Exhibit I: Dr. Reddy’s Brand’s Promises Exhibit II: Revenue Mix by Segment Exhibit III:Brief Note on the Channel Consolidation in US Exhibit IV: DRL - Revenues of the Generic Business from North America. Exhibit V: Top Pharmaceutical Corporations by US Market in 2016 Exhibit VI: Revenue data in Russia Exhibit VII: Revenue in Global Generics India Exhibit VIII: Employee Costs as per the Latest Profit & Loss Account Available Exhibit IX: Brief Snapshot of Selected Indian Pharma companies
|
|
|
|
|